FDA approves cemiplimab-rwlc for adjuvant treatment of …
On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous …
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and …
Oct 8, 2025 · The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of …
Regeneron Presents New Libtayo Data at ESMO 2025, Showcasing …
Oct 15, 2025 · - Regeneron will present new Phase 3 C-POST data at ESMO 2025 demonstrating that an every 6-week dosing regimen for Libtayo (cemiplimab) maintains similar efficacy and …
Covering Every FDA Oncology Approval From October 2025
Nov 3, 2025 · FDA Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma The FDA has approved Libtayo (cemiplimab-rwlc) for adjuvant treatment in adults with cutaneous …
FDA Approves Cemiplimab as Adjuvant Treatment for …
Oct 8, 2025 · Cemiplimab's approval is supported by findings from the C-POST clinical trial. The FDA approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant …
Regeneron Receives FDA Approval for Libtayo; 68% Risk …
Oct 8, 2025 · Regeneron (NASDAQ: REGN) announced FDA approval of Libtayo (cemiplimab-rwlc) as the first and only immunotherapy for adjuvant treatment of cutaneous squamous cell …
LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk …
FDA approves Libtayo for high-risk CSCC after surgery and …
Oct 8, 2025 · TARRYTOWN, N.Y. - The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals’ (NASDAQ:REGN) Libtayo (cemiplimab-rwlc) as an adjuvant …
Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs.com
Oct 9, 2025 · FDA approval history for Libtayo (cemiplimab-rwlc) used to treat Squamous Cell Carcinoma, Basal Cell Carcinoma, Non Small Cell Lung Cancer. Supplied by Sanofi
Libtayo® (cemiplimab-rwlc) Approved in US for Adjuvant Treatment …
Oct 15, 2025 · “This approval provides patients with CSCC at high risk of disease recurrence following surgery and radiation a much-needed option, as Libtayo is the only immunotherapy …